Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

As Management Talent Moves To China Startups, Will Industry See More In-Licensing Deals?

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Beijing-based biotech startup BeiGene Ltd. announced its first in-licensing deal this month for two clinical-stage oncology compounds from Janssen Pharmaceutical NV, a division of Johnson & Johnson.

You may also be interested in...



BeiGene CEO John Oyler On Investing In Biotech In China: An Interview With PharmAsia News (Part 2 of 2)

BeiGene CEO John Oyler discusses what is missing in China’s venture capital environment if it truly wants to foster innovation. Based in Beijing, BeiGene’s lead product entered the clinic in 2013.

BeiGene CEO John Oyler On Investing In Biotech In China: An Interview With PharmAsia News (Part 1 Of 2)

BeiGene CEO John Oyler discusses what is missing in China’s venture capital environment if it truly wants to foster innovation. Based in Beijing, BeiGene’s lead product entered the clinic in 2013.

China Innovation Takes Another Step: Merck KGAA Ties Up With BeiGene On Global Agreement For BRAF Inhibitor

In a win for China’s innovation strategy, leading local player BeiGene partners its second-generation BRAF inhibitor, which may have opportunities beyond metastatic melanoma where Roche has made its mark with BRAF inhibitor Zelboraf.

Related Content

UsernamePublicRestriction

Register

SC076521

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel